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The biosynthesis of coenzyme A (CoA) from pantothenate and the utilization of CoA in essential biochemical pathways
represent promising antimalarial drug targets. Pantothenamides, amide derivatives of pantothenate, have potential as an-
timalarials, but a serum enzyme called pantetheinase degrades pantothenamides, rendering them inactive in vivo. In this
study, we characterize a series of 19 compounds that mimic pantothenamides with a stable triazole group instead of the
labile amide. Two of these pantothenamides are active against the intraerythrocytic stage parasite with 50% inhibitory
concentrations (IC50s) of50 nM, and three others have submicromolar IC50s. We show that the compounds target CoA
biosynthesis and/or utilization. We investigated one of the compounds for its ability to interact with the Plasmodium fal-
ciparum pantothenate kinase, the first enzyme involved in the conversion of pantothenate to CoA, and show that the com-
pound inhibits the phosphorylation of [14C]pantothenate by the P. falciparum pantothenate kinase, but the inhibition does
not correlate with antiplasmodial activity. Furthermore, the compounds are not toxic to human cells and, importantly, are
not degraded by pantetheinase.
Due to drug resistance by Plasmodium falciparum, the parasiteresponsible for malaria, it is vital to identify new chemother-
apeutics targeting novel parasite pathways. P. falciparum does not
survive its asexual red blood cell (RBC) stage without access to
exogenous pantothenate (vitamin B5) (1–3). Pantothenate is me-
tabolized by five enzymes into coenzyme A (CoA), a cofactor es-
timated to be required by 9% of all enzymes (4). The first enzyme
in the CoA biosynthetic pathway is pantothenate kinase (PanK),
which catalyzes the phosphorylation of pantothenate into phos-
phopantothenate. Several pantothenate analogues have been
shown to inhibit the growth of P. falciparum in vitro, including
pantothenol (5), CJ-15,801 (6), and various other analogues (7,
8). Pantothenol (Fig. 1) has also been shown to possess antiplas-
modial activity in vivo in a mouse model of malaria (5). Recently,
pantothenamides, amides of pantothenate initially investigated
for antibacterial activity (9–11), have been shown to possess po-
tent antiplasmodial activity (12). Unfortunately, the effectiveness
of pantothenamides as antiplasmodials is attenuated by panteth-
einase (12), an enzyme found in human serum (13). The endog-
enous substrate of pantetheinase is pantetheine, which is broken
down by pantetheinase into pantothenate and cysteamine (14).
Pantetheinase also breaks down pantothenamides (12), including
the prototypical pantothenamide, N-pentylpantothenamide
(N5-Pan [Fig. 1]). The breakdown of pantothenamides is an ob-
stacle that needs to be overcome if these compounds are to be of
any use as antimicrobial agents.
There are two obvious ways by which the breakdown of pan-
tothenamides by pantetheinase can be prevented: (i) development
of a pantetheinase inhibitor that can be coadministered with the
pantothenamide, a strategy recently demonstrated to be possible
in vitro (15), or (ii) modification of the pantothenamide structure
so that it is insensitive to pantetheinase-mediated degradation
while still maintaining its antiplasmodial activity. The latter strat-
egy has been employed by de Villiers et al. (16) and, more recently,
by Macuamule et al. (17) with incomplete success, as either anti-
plasmodial activity was decreased or pantetheinase resistance was
not complete.
Triazoles can act as amide bioisosteres due to their hydrogen
bonding abilities and structural properties, including geometry
and interatomic distances (18). In this study, we characterize a
new series of 19 pantothenamide derivatives in which a triazole
group is used as a rigidified, amide isostere to replace the panteth-
einase-susceptible amide group.
MATERIALS AND METHODS
Parasite culture. P. falciparum parasites (strain 3D7) at the red blood cell
stage were maintained in continuous culture using an adaptation (19) of a
previously described method (20). The parasites were grown within hu-
man erythrocytes at 4% hematocrit in RPMI 1640 medium supple-
mented with glucose (11 mM), hypoxanthine (200 M), gentamicin (24
g/ml), and Albumax II (0.6%, wt/vol), the source of pantetheinase in the
parasite culture medium (12). The cultures were incubated at 37°C with
gentle agitation (to prevent settling of erythrocytes) under an atmosphere
of 96% nitrogen, 3% carbon dioxide, and 1% oxygen. The parasites were
maintained at a parasitemia of 5 to 10% by adding fresh uninfected
RBCs, as appropriate. To prepare pantetheinase-free parasite culture me-
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dium, the fully reconstituted medium described above was incubated at
37°C in the presence of light for 40 h, as described previously (12).
Antiplasmodial activity assay.The in vitro antiplasmodial activities of
selected compounds were investigated using the previously described ma-
laria SYBR Safe-based fluorescence assay (21), with minor modifications.
The outer wells of a 96-well plate contained 200 l of medium to negate
the “edge effect” (22). One of the plate columns contained chloroquine
(0.25 M) and was used as a positive control (i.e., 100% inhibition of
parasite proliferation). Another column did not contain any drugs and
served as a 100% parasite proliferation control. The remaining columns
included eight 2-fold dilutions of the test compounds (final volume, 100
l), with the highest concentration depending on the compounds’ po-
tency. Infected RBCs with parasites at the ring stage (parasitemia set to
0.5%) were added to each well (100l) such that the final hematocrit was
0.25% and the final total volume was 200 l. Technical repeats (n  3)
were included for each condition. Chloroquine was dissolved in H2O, and
all the other compounds were dissolved in dimethyl sulfoxide (DMSO).
The plate was incubated at 37°C in an atmosphere of 96% nitrogen, 3%
carbon dioxide, and 1% oxygen for 96 h. Thereafter, the plate was placed
at 20°C overnight or processed immediately. For processing, the plate
was defrosted (if frozen) and the content of each well was resuspended by
pipetting. Next, for each well, 100l was transferred to the corresponding
well of a new 96-well plate. A 100-l aliquot of SYBR Safe (0.2 l/ml) in
lysis buffer (KH2PO4-K2HPO4, 10 mM, adjusted to pH 7.4 with KOH)
was then added to each well. The amount of fluorescence from each well
was measured with a FLUOstar Optima multidetection microplate reader
(BMG Labtech) with 490-nm excitation and 520-nm emission wave-
lengths. The fluorescence from the chloroquine control wells was sub-
tracted from the fluorescence readings in the other wells before further
analysis. Sample fluorescence, as a percentage of the fluorescence mea-
sured in drug-free control wells, was then plotted against the test com-
pound concentration on a log scale. SigmaPlot for Windows version 11.0
(Systat Software) was then used to fit sigmoidal curves to the data. The
concentration of the compounds resulting in a 50% decrease in parasite
proliferation (50% inhibitory concentration [IC50]) was determined.
HFF cytotoxicity assay. Confluent human foreskin fibroblasts (HFF
cells) (in a 75-cm2 flask) were harvested by treatment with 1 trypsin–
EDTA (0.25% trypsin 0.2 g/liter EDTA) and diluted in 21 ml of RPMI
1640 with 10% fetal bovine serum (7). Cytotoxicity assays using 96-well
plates were set up in a manner similar to that described for the antiplas-
modial assay but included cycloheximide (10 M) as a positive control
(instead of chloroquine). The plates were incubated at 37°C in a CO2
incubator for 48 h or until the HFF cells in the drug-free control wells
became confluent (up to 62 h). Thereafter, 150 l of the medium from
each well was removed carefully so as to not disturb the cells on the bot-
tom of the wells, and the plates were placed at20°C overnight. The next
day, 150l of the SYBR Safe lysis buffer (see above) was added to each well
of the plate, and the fluorescence was measured (and data were analyzed)
as described above for the antiplasmodial activity assay.
P. falciparum andHFF lysate preparation. Cultured 3D7 parasites at
the trophozoite stage were released from RBCs with saponin (final con-
centration, 0.05% [wt/vol]) (23), and the isolated parasites were washed
three times in 1 ml malaria saline (125 mM NaCl, 5mM KCl, 25 mM
HEPES, 20 mM glucose, 1 mM MgCl2, and pH adjusted to 7.1), with
separation by centrifugation at 14,000  g for 40 s before being resus-
pended in 1 ml of the malaria saline and stored at 37°C. The parasites were
then resuspended in a potassium-buffered (KH2PO4-K2HPO4 [10 mM])
hypotonic solution, adjusted to pH 7.4, in order to lyse the cells (23). The
cells were then triturated to facilitate rupture of the parasite plasma mem-
brane. The crude lysate was centrifuged at 17,000 g and 4°C for 30 min,
and the clarified lysate (supernatant) was carefully aspirated, transferred
to a new tube, and stored at20°C until required.
HFF cells were detached from their flask by treatment with trypsin
(0.25%)–EDTA (0.2 g/liter). Cells were resuspended in 1 ml of potassium
lysis buffer (KH2PO4-K2HPO4 [10 mM]) adjusted to pH 7.4 and stored at
20°C until required.
Phosphorylation assays. Phosphorylation assays were carried out as
recently described (24). The assay makes use of the Somogyi reagent
[Zn(OH)2 and Ba(OH)2], which precipitates phosphorylated reaction
products. We utilized the assay to determine whether the phosphorylation
of [14C]pantothenate was inhibited by the pantothenate analogues. The
compounds were serially diluted and added to either P. falciparum or HFF
lysates. Single time points, within the linear phase of the phosphorylation
reaction, were used. For lysates prepared from P. falciparum, this was 40
min. For HFF cell lysates, we determined that the reaction was linear for at
least 120 min (data not shown), and this time point was used as it gave a
better signal-to-noise ratio than did earlier time points.
Statistical analysis. Unless otherwise indicated, values are presented
as means  standard errors of the means (SEM). To determine whether
the difference between the means of two groups was statistically signifi-
cant, we carried out confidence interval (CI) analyses using SigmaPlot for
Windows version 11.0 (Systat Software, Inc.). The reported CI indicates
the 95% confidence interval of the difference between the means. A
“power” value between 0.8 and 1 indicates a statistically significant differ-
ence. Power values of	0.8 are not statistically significant. Linear regres-
sion and nonlinear regression analysis was carried out using SigmaPlot.
Compound synthesis. Full details regarding compound synthesis are
included in the Supplemental text in the supplemental material.
RESULTS
Triazole-containing compound 1e (Fig. 2A, Table 1), previ-
ously reported as part of an investigation into the structural
requirements for substrate binding to the Escherichia coli PanK
(25), was identified as a more-stable derivative of N5-Pan.
Based on the description of how the triazole may mimic amide
bonds by Genazzani and coworkers, a closer mimic of N5-Pan
would have had its triazole moiety one carbon further away
from the pantoyl group than does compound 1e; however,
docking studies with selected CoA-binding enzymes suggest
that compound 1e might be a better mimic of N5-Pan (note
that three-dimensional [3D] structures have not been reported
for any of the P. falciparum CoA biosynthesis enzymes). Follow-
ing synthesis of compound 1e, its in vitro antiplasmodial activ-
ity was tested in the presence or absence of pantetheinase ac-
tivity (Fig. 2A). Compound 1e was found to be an effective
antiplasmodial against the asexual RBC stage of the parasite’s
life cycle, in both the presence and absence of pantetheinase
activity, with IC50s of 56  5 nM (n  9) and 59  6 nM (n 
2), respectively. These data are consistent with compound 1e
being completely stable in the presence of pantetheinase during
the 96-h assay. Isobutyl pantothenamide, a compound shown pre-
viously to be degraded by pantetheinase (12), was included as a
positive control (Fig. 2B). As expected and unlike compound
FIG 1 Structures of pentylpantothenamide (N5-Pan), its pantetheinase deg-
radation products, and pantothenol. The pantetheinase-sensitive amide bond
in N5-Pan and the hydroxy group in pantothenol are shown in blue.
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1e, the antiplasmodial activity of isobutyl pantothenamide was
reduced (70-fold) in the presence of pantetheinase activity.
To determine whether compound 1e was acting on the CoA
biosynthesis and/or utilization pathway, its antiplasmodial activ-
ity was tested in the presence of 100 M pantothenate, which is
100 times more than the pantothenate concentration in stan-
dard medium. As can be seen in Fig. 2A, the higher pantothe-
nate concentration completely attenuated the effect of com-
pound 1e, consistent with the compound targeting the CoA
biosynthesis and/or utilization pathway. Whether compound
1e was toxic to human cells was next investigated by exposing
HFF cells to compound 1e at concentrations of up to 10 M,
200-fold the IC50 against the parasite. No toxicity was observed
(Fig. 2A).
On the basis of the data obtained with compound 1e, a series of
analogues was created (Fig. 3 and Table 1), to determine struc-
ture-activity relationships. Based on previous pantothenamide
studies (4), it was envisaged that changing the length of the carbon
chain of compound 1e might have a large effect on activity. Com-
pounds 1a to j were designed to verify this hypothesis. The target
scope also included a variety of N-substituents to verify the effect
of branching, with (compound 1r) or without (compounds 1k
and 1l) cyclization, aromatic rings of various electron densities
(compounds 1m to q), including a 1,3-benzodioxole group (as in
compound 1o) inspired from a previously reported pantothena-
mide (16). In all cases, the triazole group was maintained to ensure
resistance to pantetheinase. Compound 1a was synthesized directly
from 1H-1,2,3-triazole-5-methanamine (Fig. 3). The synthetic path
used to access the triazole-containing pantothenamides 1b to r (Fig.
3) begins with the Boc (tert-butyloxycarbonyl) protection of propar-
gylamine to yield compound 3. Next, a two-step one-pot process,
involving first the formation of the desired azide from the corre-
sponding bromide, followed by a 1,3-dipolar cycloaddition with
compound 3, generated the 1,4-substituted regioisomers 5b to 5r
selectively. The copper-catalyzed cycloaddition was optimized by
performing the reaction in a sealed vessel (to counteract the vola-
tility of compounds 4b to r), which increased yields up to 80%,
from 40% in an open vessel. Next, Boc deprotection of com-
pounds 5b to r was followed by a reaction with D-pantolactone,
either with purification of the intermediate (compounds 6k, l, m,
o, p, r) or not (for compounds 5b to j, n, q). The latter proved to be
less efficient.
The in vitro antiplasmodial activity of compounds 1a to r, mea-
sured in the presence of pantetheinase, is shown in Table 1. Com-
pounds 1a to j served to investigate the relationship between the
length of the hydrocarbon chain at the R position and the anti-
plasmodial activity of the compounds. A direct relationship was
found between the length of the hydrocarbon tail and the com-
pounds’ IC50s (Fig. 4A), with the IC50 decreasing as the number of
carbons is increased up to 4 and then increasing as the length is
increased beyond 6 carbons. There were a total of four com-
pounds (1d to g) in this series that had submicromolar IC50s, with
the most potent compound, 1f, having an IC50 of 55 5 nM (n
7), very similar to that of compound 1e (56 5 nM, n 9).
An additional series of compounds (1k to r) included more
chemical diversity, but most of these were not as effective as
compounds 1e or 1f. Interestingly, however, branched com-
FIG 2 Comparison of in vitro antiplasmodial activity, serum stability, and cytotoxicity of compound 1e (A) and the pantetheinase-susceptible isobutyl
pantothenamide (B) under various conditions. (A) Dose-response relationship of compound 1e in the presence (black circles) and absence (white triangles) of
pantetheinase. The effect of increasing the concentration of pantothenate (from 1M to 100M) in the presence of pantetheinase on the antiplasmodial activity
of compound 1e was also tested (gray circles). The white circles show the lack of an effect of compound 1e on the proliferation of HFF cells. (B) Isobutyl
pantothenamide activity against the parasite was tested in the presence (black circles) and absence (white triangles) of pantetheinase. This assay served as a
positive control and was carried out in paired experiments with compound 1e. The data are averaged from 2 to 9 independent experiments, each carried out in
triplicate. Error bars represent the range divided by 2 (if n 2) or SEM (if n 3).
FIG 3 Synthetic scheme for the preparation of compounds 1a through 1r.
Specific yields can be found in Table S1 in the supplemental material.
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pound 1k, which has the same number of carbon atoms as
compound 1f, had a submicromolar IC50 (Table 1). Moreover,
compounds 1d and 1l, which also have the same number of
carbon atoms, have similar activities, with the branched com-
pound 1l being less active. In order to confirm the optimal
positioning of the amide-mimicking triazole group, a com-
pound in which the triazole ring of compound 1e is shifted two
carbon atoms down the chain was designed (Table 1, com-
pound 2). It was synthesized as previously reported (25). As
expected, the antiplasmodial activity of compound 2 against
asexual, blood-stage P. falciparum was significantly less than
that of compound 1e, with an IC50 of 3.5 1.2 M (n 3; CI
2.0 to 4.9 M, power 0.998).
Although less potent than compound 1e, compound 2 also
inhibited parasite growth by targeting the CoA biosynthesis/utili-
zation pathway as demonstrated by the fact that 100 times the
normal pantothenate concentration in the culture medium antag-
onized, at least partially, its antiplasmodial activity (Fig. 4B).
Taken together, these data support our hypothesis that the triazole
moiety of compounds 1a to r mimics the labile amide group of
pantothenamides yet is resistant to hydrolysis.
The activities of the compounds that, in addition to compound
1e, exhibited submicromolar IC50s against the parasite (i.e., com-
pounds 1d, 1f, 1g, and 1k) were next investigated in more detail.
In the presence of 100 M pantothenate, the antiplasmodial
activity of all four compounds was antagonized, consistent
with the compounds acting on the target pathway (Fig. 5). The
compounds were not toxic to HFF cells at concentrations of up
to 100 M (Fig. 5).
Additional experiments were carried out with compound 1e
(and compound 2 as a control) to investigate further its mecha-
nism of action. Specifically, we looked for a correlation between
the antiplasmodial activity of the compounds and their activity
against a possible target. Given the similarity of compound 1e
to pantothenate, compound 1e was expected to interact with
PanK, the first enzyme involved in CoA biosynthesis. The
TABLE 1 Antiplasmodial activity of modified pantothenamides that contain a triazole with
different substituents attached at the R position
a In medium containing pantetheinase. IC50s are averaged from three or more independent experiments, each
carried out in triplicate.
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phosphorylation of [14C]pantothenate by PanK in P. falciparum
lysates (23) following a 40-min incubation was determined in
the presence of increasing concentrations of compounds 1e or
2 (Fig. 6). As expected, it was found that as the concentration of
compounds 1e or 2 was increased, the amount of [14C]panto-
thenate phosphorylated by the P. falciparum lysate was reduced.
Surprisingly, however, compound 1e was significantly less ef-
fective at inhibiting pantothenate phosphorylation (IC50, 1.1
0.1 M; n 3) compared to its antiplasmodial activity (IC50
56  5 nM; CI  0.96 to 1.21 M; power  1), while com-
pound 2 was equally effective at inhibiting pantothenate phos-
phorylation (IC50 0.6 0.1 M; n 3) and parasite growth
(IC50  3.5  1.2 M; CI  6.4 to 0.6 M; power  0.348).
Although the potency of compound 1e and that of compound 2
at inhibiting pantothenate phosphorylation by P. falciparum
PanK were similar (	2-fold difference), they were statistically sig-
nificantly different (CI 0.36 to 0.65 M; power 1.0).
The fact that the difference observed in the antiplasmodial
IC50s of compounds 1e and 2 is not carried through in the
pantothenate phosphorylation assay points to the target of
compound 1e being something other than PanK. This is further
supported by our observation that N5-Pan, the benchmark
pantothenamide to which compound 1e is the closest mimic
(10), inhibits phosphorylation of [14C]pantothenate by P. fal-
ciparum lysates with an IC50 of 0.13 0.03 M (n 3) (see Fig.
S1 in the supplemental material), making it 8-fold more active
than compound 1e in this assay (CI 0.7 to 1.3 M; power
1.0) despite being 35-fold less active in the in vitro antiplasmo-
dial assay (IC50 2 0.2 M in the absence of pantetheinase)
(12).
To examine whether the lack of activity of compound 1e (and
other analogues) against HFF cell viability was due to a poor in-
teraction between compound 1e and the HFF cell PanK, the ability
of compounds 1e and 2 to inhibit [14C]pantothenate phosphory-
lation by PanK in lysates prepared from HFF cells was also tested.
The results show that both compounds inhibited the phosphory-
lation of [14C]pantothenate by HFF cell lysate, with IC50s of 5.2
0.4 M (n  3) for compound 1e and 1.6  0.5 M (n  3) for
compound 2. These values are similar to those obtained for com-
pounds 1e and 2 when tested against the P. falciparum PanK
(1.1 0.1M and 0.6 0.1M, respectively), consistent with the
lack of cytotoxicity by the analogues against HFF cells not being
due to a lack of an interaction with the HFF PanK.
FIG 4 (A) Relationship between the length of the hydrocarbon side chain (at the R position) of compounds 1a to j and their antiplasmodial IC50s. The IC50 for
compound 1a (white symbol) could not be determined because it is higher than the highest concentration tested (100 M), which had	10% inhibitory effect.
The assay was carried out in the presence of pantetheinase activity and 1 M pantothenate. (B) In vitro antiplasmodial activity of compound 2. Dose-response
relationship of compound 2 in the presence (black circles) of pantetheinase. The effect of increasing the concentration of pantothenate (from 1 M to 100 M)
in the presence of pantetheinase on the antiplasmodial activity of compound 2 was also tested (gray circles). Values are means from three or more independent
experiments, each carried out in triplicate. Where not shown, the error bars (SEM) are smaller than the symbols.
FIG 5 In vitro antiplasmodial activity and cytotoxicity screening of a se-
lection of the compounds tested. The antiplasmodial activity of the com-
pounds was tested in the presence of pantetheinase in medium containing
1 M (black circles) or 100 M pantothenate (gray circles). The white
circles show cytotoxicity screens performed against HFF cells using con-
centrations (up to 100 M) much higher than those required to inhibit
parasite growth (IC50  55 nM to 0.54 M). The data are averaged from
three independent experiments, each carried out in triplicate, and the error
bars represent SEM.
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DISCUSSION
Pantothenamides may be considered promising leads for the de-
velopment of new antimalarial agents due to their excellent po-
tency against P. falciparum (some with IC50s comparable to that of
chloroquine against the RBC stage of the parasite), the fact that
they act on a pathway not targeted by current drugs (12, 17), and
their low toxicity against mammalian cells (7, 17). Their suscepti-
bility to degradation by serum pantetheinase (12), however, has
prevented their further development.
In this study, we show that replacement of the susceptible
amide moiety of pantothenamides with a triazole isostere pro-
duces pantothenamide-mimicking compounds, which, for the
first time, both show nanomolar antiplasmodial activity and are
fully resistant to pantetheinase activity. In particular, one of the
most active triazoles, compound 1e (IC50  56 nM), is also the
closest mimic to the benchmark compound N5-Pan but is much
more potent (N5-Pan; 2 M in the absence of pantetheinase)
(12). A further six triazole-bearing analogues (1f, 1l, 1m, 1n,
1p, 1q) resemble pantothenamides tested previously for anti-
plasmodial activity in pantetheinase-free medium (16). The
triazole-bearing compounds were equivalent to (for com-
pound 1l), or between 2 times (compound 1q) and 
45 times
(compound 1m) more potent than the pantothenamides that
they mimic. The triazole moiety, therefore, not only prevents
pantetheinase-mediated degradation of these compounds but
also enhances their antiplasmodial potency. One possible explana-
tion for the enhanced activity is the fact that the triazole group is
more rigid than an amide bond, which may reduce the entropic
cost of binding to the target. It is well established that by re-
ducing this entropic term, the overall free energy of binding
can be improved dramatically (26).
We also show that compound 1e is about 60 times more effec-
tive than compound 2 at inhibiting the RBC stage of the parasite’s
life cycle, yet both were much less potent in the kinase assay than
the antiplasmodial activity of compound 1e. This, together with
our observation that N5-Pan is a much weaker antiplasmodial yet
more potent inhibitor of pantothenate phosphorylation than
compound 1e, is consistent with PanK not being the target of
compound 1e. Moreover, the transport of pantothenate into the
parasite is an unlikely target in light of the fact that it takes place via
a low-affinity (Km,23 mM) transport mechanism (27), whereas
the antiplasmodial activity of compound 1e is in the nanomo-
lar range. Nevertheless, the observation that the antiplasmodial
effect of compound 1e (and the other analogues tested) can be
antagonized by increasing the extracellular concentration of
pantothenate (Fig. 2 and 5) is consistent with the compound
acting on the CoA biosynthesis and/or utilization pathway. An
alternative interpretation whereby compound 1e has a mecha-
nism of action that is unrelated to CoA biosynthesis/utilization
but its uptake into the parasite is reduced when the extracellu-
lar pantothenate concentration is increased to 100 M (via
competition at the pantothenate transporter) can be excluded
because the transporter would not be saturated under these
conditions (i.e., at substrate concentrations that are 230-fold
lower than the Km of the transporter). The target of compound
1e is therefore likely to be downstream of PanK (4). Alterna-
tively, compound 1e (and not compound 2) may accumulate
within the intact parasite to the micromolar level required to
inhibit pantothenate phosphorylation by PanK.
Our data are consistent with the compounds being nontoxic.
Given that compound 1e is equally as effective at inhibiting pan-
tothenate phosphorylation by PanK from both P. falciparum and
HFF cells, a possible explanation for the lack of activity against
HFF cells is that the compounds may not permeate the latter cell
type. The high specificity of the human sodium-dependent mul-
tivitamin transporter (SMVT) and the previous demonstration
that several triazole-conjugated molecules are not substrates of the
human SMVT are consistent with this explanation (28).
We have characterized a series of novel rigidified pantothe-
nate-mimicking analogues that show potent antiplasmodial activ-
ity by targeting the CoA biosynthesis/utilization pathway. The in-
corporation of a strategically positioned triazole group renders the
compounds resistant to degradation by pantetheinase in human
serum. Furthermore, as they appear to be nontoxic to human cells,
we believe that compounds 1d to g and k are potential lead com-
pounds for the development of a novel antimalarial. Whether they
have additional, hitherto-unknown liabilities that prevent them
FIG 6 Effect of compounds 1e and 2 on [14C]pantothenate phosphorylation by P. falciparum (A) and HFF cell (B) lysates. PanK activity was detected using
[14C]pantothenate and Somogyi reagent. The assay was carried out for 40 min (P. falciparum) or 120 min (HFF cells) in the presence or absence of increasing
concentrations of compound 1e (white circles) and compound 2 (black circles). Data are expressed as a percentage of the total amount of [14C]pantothenate
phosphorylated in the absence of inhibitors and are averaged from three independent experiments (SEM), each carried out in duplicate.
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from being active in vivo remains to be determined and will be
investigated in future work.
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